RxDoctor Payments Data

Haley Quillen

Family · Greeneville, TNNPI 1902151616

Payments from drug & device makers

$2,759in general payments, 2019–2025

Across 138 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$768
  • AbbVie$661
  • Novo Nordisk$623
  • Lilly USA, LLC$262
  • Takeda Pharmaceuticals U.S.A., Inc.$80
  • Astellas Pharma US Inc$65
  • plus $300 from 11 others

What the payments were for

  • Food & beverage$2,69498%
  • Education$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,759 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$15,571
Medicare patients
33
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide62$69,421
JardianceEmpagliflozin20$33,142
OzempicSemaglutide15$25,696
EliquisApixaban34$23,701
Tresiba Flextouch U-100Insulin Degludec19$9,148
Aripiprazole18$1,772
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen64$1,734
Omeprazole93$1,636
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,544
Celecoxib46$1,120
Gabapentin64$624
Duloxetine Hcl26$589
Albuterol Sulfate HfaAlbuterol Sulfate34$584
Levothyroxine Sodium73$541
Tramadol Hcl47$522

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$262$69,42162 claims
Novo NordiskOzempic$623$25,69615 claims
PfizerEliquis$29$23,70134 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Greeneville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →